2023
Association of MTHFR Polymorphisms With Leukoencephalopathy Risk in Patients With Primary CNS Lymphoma Treated With Methotrexate-Based Regimens
Karschnia P, Kurz S, Brastianos P, Winter S, Gordon A, Jones S, Pisapia M, Nayyar N, Tonn J, Batchelor T, Plotkin S, Dietrich J. Association of MTHFR Polymorphisms With Leukoencephalopathy Risk in Patients With Primary CNS Lymphoma Treated With Methotrexate-Based Regimens. Neurology 2023, 101: e1741-e1746. PMID: 37527941, PMCID: PMC10624483, DOI: 10.1212/wnl.0000000000207670.Peer-Reviewed Original ResearchConceptsPrimary CNS lymphomaCNS lymphomaHD-MTXMethylenetetrahydrofolate reductaseResponse to induction therapyAssociation of MTHFR polymorphismsMethotrexate-based regimensSeverity of leukoencephalopathyProgression-free survivalHigh-dose methotrexateRisk of leukoencephalopathyAssociated with increased frequencyAssociated with leukoencephalopathyInduction chemotherapyDecreased functional statusInduction therapyOverall survivalMassachusetts General HospitalMTX clearanceMTHFR polymorphismsFolate depletionLeukoencephalopathyPatientsElevated riskFunctional statusClinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system
Renovanz M, Kurz S, Rieger J, Walter B, Becker H, Hille H, Bombach P, Rieger D, Grosse L, Häusser L, Skardelly M, Merk D, Paulsen F, Hoffmann E, Gani C, Neumann M, Beschorner R, Rieß O, Roggia C, Schroeder C, Ossowski S, Armeanu-Ebinger S, Gschwind A, Biskup S, Schulze M, Fend F, Singer S, Zender L, Lengerke C, Brucker S, Engler T, Forschner A, Stenzl A, Kohlbacher O, Nahnsen S, Gabernet G, Fillinger S, Bender B, Ernemann U, Öner Ö, Beha J, Malek H, Möller Y, Ruhm K, Tatagiba M, Schittenhelm J, Bitzer M, Malek N, Zips D, Tabatabai G. Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system. Neuro-Oncology Advances 2023, 5: vdad012. PMID: 36915613, PMCID: PMC10007909, DOI: 10.1093/noajnl/vdad012.Peer-Reviewed Original ResearchBiomarker-guided therapyAdult patientsMolecular profilingNeuro-oncology patientsAdvanced tumorsClinical utilityTargeted therapyNervous systemClinical trialsTherapy recommendationsComprehensive molecular profilingInclusion of patientsData cutoffClinical benefitClinical outcomesTumorTherapyPatientsEvidence levelClinical careTrialsMtbTranslation studiesInvestigate feasibility
2020
Clinical neuro-oncology for the neurologist.
Lukas R, Taylor J, Kurz S, Mohile N. Clinical neuro-oncology for the neurologist. Neurology Clinical Practice 2020, 10: 458-465. PMID: 33299675, PMCID: PMC7717629, DOI: 10.1212/cpj.0000000000000765.Peer-Reviewed Original ResearchNeuro-oncologyReclassification of tumorsClinical neuro-oncologyClinical practiceClinically relevant pointsCNS lymphomaNeuro-oncology patientsBrain metastasesInfiltrating gliomasBrain tumorsStandard managementAdult neurologistsTumorPatient carePatientsMolecular characteristicsEvolving fieldNeurologistsBrainLymphomaMetastasisMeningiomasGliomaCNSClinicNeuro-Oncology Practice Clinical Debate: Early treatment or observation for patients with newly diagnosed oligodendroglioma and small-volume residual disease
Fogh S, Boreta L, Nakamura J, Johnson D, S A, Kurz S. Neuro-Oncology Practice Clinical Debate: Early treatment or observation for patients with newly diagnosed oligodendroglioma and small-volume residual disease. Neuro-Oncology Practice 2020, 8: 11-17. PMID: 33664965, PMCID: PMC7906263, DOI: 10.1093/nop/npaa037.Peer-Reviewed Original ResearchResidual diseaseWorld Health Organization grade IISmall-volume residual diseaseMacroscopic residual diseaseTreated with procarbazineTreatment of oligodendrogliomasUp-front treatmentTreatment of brain tumorsBenefits of treatmentDelayed therapyMedian survivalVincristine chemotherapyGrade IIDiagnosed oligodendrogliomaMinimal toxicityEffective therapyEarly treatmentClinical trialsDelayed toxicityBrain tumorsPatientsChemoradiotherapyChemotherapyOligodendrogliomasTherapyINO-5401 and INO-9012 delivered intramuscularly (IM) with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma (GBM): Interim results.
Reardon D, Brem S, Desai A, Bagley S, Kurz S, De La Fuente M, Nagpal S, Welch M, Hormigo A, Carroll N, Bartra S, Campbell P, Bhatt K, Lowy I, Boyer J, Kraynyak K, Morrow M, McMullan T, Weiner D, Skolnik J. INO-5401 and INO-9012 delivered intramuscularly (IM) with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma (GBM): Interim results. Journal Of Clinical Oncology 2020, 38: 2514-2514. DOI: 10.1200/jco.2020.38.15_suppl.2514.Peer-Reviewed Original ResearchNewly-diagnosed GBMTumor inflammationCohort AT cell responsesNewly diagnosed glioblastomaWeeks of treatmentCheckpoint inhibitionPD-1Cohort B.Combination therapyPrimary endpointCD8+T cellsPhase I/IICohort BPlatelet countLymphocyte countSafety profileCemiplimabSurvival advantageCohort studyLytic potentialFlow cytometryPatientsGlioblastomaCohort
2019
HOUT-29. THE INFLUENCE OF PSYCHIATRIC ILLNESS ON OUTCOME AND CANCER CARE RECEIVED IN PATIENTS WITH GLIOMAS
Patel P, Li T, Chou J, Patel A, Crispino S, Utate M, Kurz S. HOUT-29. THE INFLUENCE OF PSYCHIATRIC ILLNESS ON OUTCOME AND CANCER CARE RECEIVED IN PATIENTS WITH GLIOMAS. Neuro-Oncology 2019, 21: vi118-vi118. PMCID: PMC6846933, DOI: 10.1093/neuonc/noz175.494.Peer-Reviewed Original ResearchCancer carePsychiatric illnessPsychiatric diagnosisTumor diagnosisFollow-upPrevalence of psychiatric disordersPresence of psychiatric illnessKaplan-Meier methodPsychiatric disordersPsychiatric conditionsTime of diagnosisSubstance use problemsCompared to controlsAnaplastic oligodendrogliomaMedical careAnaplastic astrocytomaIntracranial gliomasCompare complianceAdjustment disorderIncreased riskPoor complianceGlioma patientsCompare survivalCarePatientsEpilepsy and Anticonvulsant Therapy in Brain Tumor Patients
Kurz S, Schiff D, Wen P. Epilepsy and Anticonvulsant Therapy in Brain Tumor Patients. 2019, 717-728. DOI: 10.1007/978-3-030-04152-6_39.Peer-Reviewed Original ResearchBrain tumor patientsTumor patientsTumor locationAntiepileptic drugsFavorable side effect profileBrain tumorsSide effect profileAntiepileptic drug therapyHistory of seizuresFocal symptomatic epilepsyGlioneuronal tumorTumor histologyEffect profileAnticonvulsant therapyDrug therapySymptomatic epilepsySymptomatic treatmentTumorPatientsSeizure riskQuality of lifeIncreasing experienceSeizuresAnticonvulsant agentsTherapy
2018
PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma.
Kurz S, Cabrera L, Hastie D, Huang R, Unadkat P, Rinne M, Nayak L, Lee E, Reardon D, Wen P. PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma. Neurology 2018, 91: e1355-e1359. PMID: 30171077, DOI: 10.1212/wnl.0000000000006283.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBevacizumabBrain NeoplasmsFemaleGliomaHumansMaleMiddle AgedNeoplasm Recurrence, LocalNivolumabProgrammed Cell Death 1 ReceptorRetrospective StudiesSalvage TherapySurvival AnalysisTreatment OutcomeYoung AdultConceptsRecurrent high-grade gliomaHigh-grade gliomasRetrospective observational studySalvage therapySurvival benefitSingle-institution retrospective observational studyPD-1 blocking antibodiesObservational studyPD-1 inhibitionProgression-free survivalClass IV evidenceConcurrent bevacizumabAntibody nivolumabPD-1Median survivalClinical benefitImproved survivalNivolumabPembrolizumabAdult patientsBevacizumabIV evidenceClinical trialsPatient populationPatientsQuo Vadis—Do Immunotherapies Have a Role in Glioblastoma?
Kurz S, Wen P. Quo Vadis—Do Immunotherapies Have a Role in Glioblastoma? Current Treatment Options In Neurology 2018, 20: 14. PMID: 29666934, DOI: 10.1007/s11940-018-0499-0.Peer-Reviewed Original ResearchImmunotherapeutic strategiesSafety of CAR-T cell therapyCAR-T cell therapyT cells in vivoChallenges of immunotherapyCAR-T cellsT-cell therapySuccess of immunotherapyHigh-grade gliomasStudy evaluated treatmentIncreased polyclonalityDC vaccinesDiagnosed glioblastomaImmunotherapy researchRecurrent glioblastomaT cellsImmunotherapyEffective therapyClinical evidenceClinical studiesClinical trialsGlioblastoma microenvironmentGlioblastomaPatientsTherapy